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Exploring the relationship of MBD1 protein binding CpG sites of
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Shelby Scherer
Under the mentorship of Dr. Amanda Stewart
Abstract
Methylated DNA binding (MBD) proteins control transcriptional regulation by binding
methylated DNA at CpG islands to modulate transcriptional activation and silencing of
specific genes such as tumor suppressors. The goal is to explore the structure/function
relationship between MBD proteins and methylated DNA recognition. By synthesizing
the methylated DNA binding region of the MBD1 protein, binding studies test the
peptide’s affinity and specificity for methylated DNA. Fluorescence, circular dichroism,
and thermal denaturation techniques are utilized to determine the binding affinities and
structures of peptides. Studies of peptide mutations can monitor the effectiveness of
methylated DNA binding compared to the original peptide. The most structured peptide
is expected to have the highest affinity and selectivity, leading to a peptide which can
compete with the MBD1 protein for methylated DNA binding. The binding region of the
MBD1 protein is composed of a two-stranded β-sheet called a 𝛽-hairpin connected by a
large loop region. This was not observed in the initial peptide sequence. Instead the CD
indicated the structure to be random coil. This was expected, the 𝛽-hairpin portion was
synthesized without the full protein limiting favorable interactions to stabilize its
structure. However, a fluorescence binding study determined the peptide did bind DNA.
Thermal denaturation studies were conducted showing the stability of the peptide.
Mutants will be made to increase binding affinity and selectivity in the future. This
research could produce a series of peptides which can inhibit methylated DNA binding
domains and reduce the silencing of tumor suppressor proteins, providing effective
cancer therapeutics.
Thesis Mentor____________________________
Dr. Amanda Stewart
Honors Director____________________________
Dr. Steven Engel
April 2016
Chemistry Department
University Honors Program
Georgia Southern University

Introduction
Methylated DNA binding proteins are a type of transcription factor which means
they control transcriptional regulation. Transcription factors typically contain repression
and activation domains to turn genes on and off on the DNA strand1. The methyl-CpG
binding domain (MBD) proteins bind to the methylated DNA to regulate transcriptional
silencing of specific genes such as tumor suppressors2. The MDB1 protein typically
binds at methylated CpG islands which are cytosine-rich regions. The binding region
contains a β-hairpin, a β-sheet containing two β-strands linked by a β-turn or loop region,
which is known to exclusively bind the binding site in the methylated DNA.
Synthesizing the peptide sequence where the MBD protein binds to the DNA will
determine how well the protein binds without the full domain. If it does not bind, some
of the amino acids in the peptide will be substituted for those that are known to bind
DNA and will maintain β-sheet structure and folding. With the substitution of the amino
acids, the β-hairpin structure will be monitored to ensure it is maintained.
In a separate study, a different peptide was studied
and it was determined that fluoro and hydroxyl
substitutions on the hairpin result in lower stabilization
than the corresponding amine –substitution and acetylated
polyamines3. This data has been taken into consideration
for the amino acid sequences of the mutant MBD1
peptides. DNA binding molecules can disrupt CpG
methylation, silencing tumor suppressing genes by
hypermethylation of their associated CpG islands5,6.

Figure 1. MBD1 protein
binding methyl-CpG
islands in methylated
DNA. The 𝛽-sheet
indicates the binding
region of the protein.4
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Hypermethylation of CpG islands has been associated with transcriptional silencing of
various genes in cancer cells7. One of the goals in binding a peptide sequence that has a
higher affinity than the original would be to widen the minor groove of the DNA. Doing
this would disrupt the DNA methylation in the major groove8. Binding the MDB1
mutant and preventing the full MBD1 protein from binding, will hopefully enable tumor
suppressor transcription and will prevent the methylated CpG islands from inhibiting
transcription of genes like those that code for tumor suppressors.
Normally, methylated CpG islands prevent the exon from acting as a template for
receptor production9. Therefore, high levels of CpG methylation has been known to lead
to gene silencing. This could be further explored to determine whether the silencing is
caused by MBD proteins or if the protein only amplifies the methylated CpG
transcriptional inhibition.
The section of the MBD1 protein to
be synthesized and analyzed is the binding
region made up of 24 amino acids (Table 1
and Figure 2). The structure is expected to
be a random coil instead of a β-sheet since
the whole protein is not present to stabilize
the region. Mutations of the original
peptide will also be synthesized and
analyzed, and the most structured peptide is
expected to have the highest binding affinity for
the methyl-CpG islands.

Figure 2. MBD1 binding region
amino-acid chain synthesized
and capped.
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The goal is to understand the structure and function relationship between the
peptide and methylated DNA binding. Doing this can create a peptide that will
specifically bind methylated DNA and in the future have a peptide that will competitively
bind the DNA to regulate the transcription of genes such as tumor suppressors. It is
important to regulate this because silencing of tumor suppressor genes can be deadly and
expression of too many tumor suppressors could be just as devastating. The regulation of
gene expression is very important, and successfully producing a peptide with the desired
DNA binding properties is an important step in achieving this goal.
Table 1. MBD1 Peptide Sequence and Mutant Peptide Sequence
MBD1 Sequence

Ac-QWKRRESFRKSGASFGRSDIYYQS-NH2

Mutant Peptide Sequence Ac-GWKRRESWRKSGASFGRSDIYYQS-NH2
MBD1 Short Hairpin
Ac-GWKRRESWRSNGRSDIYYQS- NH2
*MBD1 sequence is the original DNA binding sequence within the MBD1 protein10.

Methods
The MBD1 binding sequence (Table 1) was synthesized by solid phase peptide
synthesis using PS3 Peptide Technologies Peptide Synthesizer. All of the amino acids
were coupled for 20 minutes and deprotected twice for 5 minutes. The solvent used was
DMF, the activator was HBTU and the deprotection solution was 20% piperidine. The
peptide was capped using acetic anhydride. After synthesis the peptide was capped and
removed from the reaction vessel with isopropanol and placed into a peptide flask. The
peptide flask was connected to a round bottom flask attached to nitrogen for bubbling.
The solution was drained and more isopropanol was added and then rinsed by
dichloromethane. The sample was rinsed again and dried. After the resin was dried, the
peptide was cleaved from the resin using a cleavage cocktail of 95% TFA, 2.5% TIPS
4

and 2.5% water. The solution was mixed and transferred into the peptide flask. Nitrogen
was added to allow a slow bubble which continued for two hours to cleave the resin from
the peptide. The solution was then drained and the resin was left in the peptide flask,
thereby releasing the peptide into the round bottom flask. About 2 ml of TFA was added
to rinse the peptide flask to ensure all peptide was removed. The peptide solution was
evaporated to a very small volume before the peptide was precipitated with 20 mL of
cold ether. About 20 ml of DI water was also added. The solution was poured into a
separatory funnel. The solution was mixed and then released into two samples. The
water layer, which contained the peptide, was collected and lyophilized to a powder.
A solution that the peptide dissolved in had to be determined. After determining a
water-based solution to dissolve the peptide, a large portion of the peptide was added to
about 5mL and filtered. An HPLC was used to purify the peptide with a C-18 silica
based reversed phase HPLC column. A two solvent system was used, solvent A, 95%
HPLC water, 5% Acetonitrile and 0.1% TFA, and solvent B, 95% acetonitrile, 5% HPLC
water and 0.1% TFA. The column was saturated with solvent A to equilibrate the
column, and solvent B, was added to the column at the end of each peptide injection to
wash the column fully. About 0.2 mL of the solution was run on the HPLC, with a 0 to
40% solvent B over 25 minutes, to determine the expected spectrum and the peptides
elution time. The peptide eluted around 16 minutes, which is about two-thirds of being
full saturated. Then, the volume was slowly increased and five different fractions were
collected at the elution time. After the peptide was purified it was placed on the
lyophilizer. After lyophilizing the peptide fractions, a small amount of peptide from each
fraction was dissolved in 50 µL of water. Then 1µL was placed on a well of the MALDI
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TOF plate and when it was almost dry 1µL of matrix was added on top of it. A Bruker
Microflex MALDI-ToF mass spectrometer, to determine the mass of each of the fractions
collected from HPLC was used to determine the mass of the peptide. Then 583µL 6M
GuHCl buffer, 100 µL peptide and 17µL of 10 mM Na2HPO4 buffer was added to a
cuvette and the absorbance was measured using a UV spectrometer at 280nm. The
absorbance was used to determine the concentration of the peptide. Then the peptide was
diluted to about 7 mM using 10mM Na2HPO4 buffer and run on the CD instrument. The
data was analyzed to determine its secondary structure.
The concentration of the single strand DNA sequences were determined to be
590µM and 485µM. Amounts of DNA were added to produce a 242 µM double helix
DNA. The DNA was then annealed and the absorbance was taken at 260 nm and then
used to determine the concentration. A fluorescence binding study was performed
maintaining 5µM MBD1 peptide concentration and increasing the methylated DNA
concentration (Table 2). Using these solutions, samples of peptide and DNA were micropipetted into a 700 µL cuvette using low retention pipette tips. The instrument used was
a fluorescence spectrometer. Each sample was run twice and then averaged.
A thermal denaturation analysis was conducted using a 10µM MBD1 peptide in
10mM Na2HPO4 solution. Then the solution was analyzed in a thermal denaturation
experiment via circular dichroism. This was conducted at 222 nm with a temperature
range of 5-95°C. The system would stand at each degree for 60 seconds and then rest for
60 seconds for a total of 90 cycles.
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A CD analysis was then performed using three samples. A10µM MBD1 peptide
in 10 mM Na2HPO4, 10 µM MBD1 peptide and 10 µM methylated DNA, and the third
contained only 10µM methylated DNA. The system was set to run from 260 to 190 nm.
Results
Synthesis and Purification of MBD1 Binding Sequence
The MBD1 peptide was synthesized, cleaved and purified twice because the first
synthesis did not couple properly. After cleaving and lyophilizing the peptide, it was
dissolved in a solvent. It was not soluble in any of the solutions containing TFA.
However, it dissolved best in about 5mL of 90% DI water and 10% acetonitrile. All
other solutions would result in it crashing out or not dissolving. It was sonicated for
many minutes throughout the peptide additions. Only small samples of peptide were
added over time to ensure it was properly dissolving. After it was dissolved, the peptide
was filtered to prevent dust and other particles from clogging the needles and HPLC.
Before each purification run, A Wash was run for 10 minutes to re-equilibrate the column
with polar solvent. After filtering the peptide, a small amount (about 200µL) was
injected into the HPLC. The system ran for the full 25 minutes to determine when the
peptide eluted. After that, larger increments of the peptide solution was added and
collected in five separate fractions. This was to ensure that the peptide was properly
purified because; each peak could contain many different peptides but the major peak
was expected to have the desired peptide. Therefore, five fractions were collected before,
during and after the major peak to separate the MBD1 peptide from sample (Figure 3).
Many sessions of fractions were collected to purify the entire peptide. After each
purification, nonpolar solvent B was run in order to remove any peptide or other
7

substance that stuck on the column. The peptide fractions were then lyophilized to be
prepared for mass spectrometry.

Figure 3. MBD1 peptide HPLC peak from 800 µL of peptide dissolved in water
Peptide Characterization
After preparing the mass spectrometer samples, the laser strikes the sample,
ionizing it and then the detector determines the mass of the products in the sample. This
was done for each of the samples. The expected mass of the synthesized peptide
sequence was 2910. The best peak was 2915 from fraction 4 (Figure 4). Fraction 3 was
expected to have the most pure peptide since it was from the top of the peak, however
this was not the case. Instead the fraction that had the peak below was used for the
remainder of the experiment.
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Figure 4. MALDI-ToF data of purified MBD1 peptide. Peak expected at 2910.
After determining that the correct peptide was present in fraction 4, the peptide
was dissolved in 10mM Na2HPO4 buffer, pH 7, to be analyzed using UV-Vis at
wavelength of 280nm. The absorbance was used to determine the concentration of the
peptide which was 31.2 µM. A peptide sample of the 31.2 µM peptide solution was
analyzed via circular dichroism (CD) to determine the structure. The peptide
concentration was diluted from 31µM to 7.5µM using the 10mM Na2HPO4. The CD
indicated the structure to be a random coil based on its minimum peak at 195nm, which is
the characteristic of a random coil peptide structure (Figure 5).
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Figure 5. CD wavelength data for 7.5µM MBD1 peptide analyzed from 260-190nm at
25°C.
Binding Studies
After determining the structure of the peptide, the single stranded methylated
DNA concentrations were determined and annealed to produce 242µM double stranded
methylated DNA. To prepare for the

Methylated Duplex DNA:
5’-G-T-A-T-C-mC-G-G-A-T-A-C-3’
3’-C-A-T-A-G-G-mC-C-T-A-T-G-5’

binding study, a constant
concentration of 5µM peptide was

Figure 6. Methylated DNA Sequence

added to each low retention tube and the
methylated DNA was added by increasing the concentration in each tube (Table 2).
Table 2. Concentrations of Peptide, Buffer, and DNA for Fluorescence binding study
Sample
1
2
3
4
5
6
7
8
9
10

Peptide (µL)
120
120
120
120
120
120
120
120
120
120

Buffer (µL)
680
673
663
647
630
614
597
581
548
515

DNA (µL)
0
7
17
33
50
66
83
99
132
165

[DNA] mM
0
2
5
10
15
20
25
30
40
50
10

Each sample was analyzed twice, using the fluorimeter to detect tryptophan fluorescence
emission scan. The two runs were averaged to produce a binding curve. The decrease of
the fluorescence intensity curve shows tryptophan quenching and indicates that the
peptide binds the DNA (Figure 7).
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Figure 7. Tryptophan fluorescence quenching analyzed using 5µM MBD1 peptide and
0 to 50µM methylated DNA.
Thermal Denaturation and Circular Dichroism Analysis
The thermal denaturation heated the MBD1 peptide from 5°C to 95°C. The
sample would heat for one minute and then equilibrate to that temperature for one minute
for a series of 90 cycles (Figure 7). For the thermal denaturation study the peptide begins
at its “fully folded” structure at 5°C and ends at 95°C where it is presumed to be fully
unfolded. The full protein would have an “S shaped” denaturation curve. However, this
peptide does not have a regularly structured beta sheet therefore, the melting temperature
is expected to be lower than the full protein or a peptide that is more structurally stable.
However, this is mainly a linear negative slope (Figure 8). The denaturation also
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provides the melting point of the peptide. The melting temperature for this MBD1
peptide was determined to be 49°C, which is the temperature in which the peptide is 50%
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Figure 8. MDB1 thermal denaturation from 5°C to 95°C using Circular Dichroism at a
constant wavelength of 222nm.
The CD analysis samples were then prepared. The 10µM MBD1 peptide in
10mM Na2HPO4, 10µM MBD1 peptide and 10µM methylated DNA, and the 10µM
methylated DNA samples were analyzed using the CD to determine their structures
(Figure 9). The peptide once again maintained the random coil structure. The reason for
the second run of the peptide was to be able to compare the structures with the same
concentration. In figure 9, the structure of the peptide, DNA, peptide and DNA (mixed)
and the peptide and DNA (additive) can be compared to show the binding of the peptide
and DNA. The peptide (grey) is expected to have a random coil signal which it does and
the DNA (blue) is expected to have a double helical structure. The peptide and DNA
mixed (orange) line and the peptide and DNA (additive) lines are not the same which
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indicate that binding is occurring. The mixed value was recorded using the CD to
visualize the structure, whereas the additive value was determined by averaging the
peptide and DNA signals. The reason for this was to determine if there was actual
binding or if the signal was a simple average of the individual signals.
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Figure 9. The circular dichroism structure study of MBD1 peptide, MBD1 peptide with
DNA and DNA (mix) and (additive).
Discussion and Conclusion
The peptide was synthesized twice because the first synthesis did not result in the
desired peptide mass on MALDI-ToF. That is the reason for the extended coupling of the
central amino acids in the sequence. Based on the mass of the first synthesized peptide, it
is thought that the alanine did not couple to the peptide properly, resulting in the incorrect
peptide mass. The second synthesis resulted in a mass very close to the expected 2910.
The peptide did not initially dissolve in many of the solutions which is under inspection
by other individuals. Researchers in the Stewart lab have determined that there is a high
concentration of sodium ion and other ions in the local water samples. It is thought that
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sodium binds to tryptophan and other amino acids in the peptide sequence, disrupting the
peptide’s structure and causing the peptide to precipitate from solution. The sodium
binding would result in disruption in the structure of the peptide and also the binding of
the peptide with the methylated DNA.
After the proper mass was determined, the CD spectrometer was used to
determine the secondary structure. The shape of the sequence when present in the full
protein consists of one β-sheet connected by a loop region, however, without the entire
peptide the structure was unknown. After running the CD, the structure was determined
to be a random coil (Figure 4). This was expected since the full peptide was not present
to help maintain the full β-sheet structure. For the mutants to be synthesized in the
future, a couple of the amino acids will be exchanged, intended to restructure the peptide
into the β-sheet-loop region- β-sheet structure of the MBD1 binding site. In the first
mutant a glutamine will be substituted for a glycine at the N terminus and a
phenylalanine will be replaced with a tryptophan in order to create a mutant peptide.
Glycine is the smallest amino acid and helps with tight loops in the beta sheets and
tryptophans are regularly found in β-sheets because their indole ring is larger. The indole
ring provides more potential pi-pi interactions to allow stacking with the DNA bases.
They also have a fluorescence quality which is helpful for binding studies. In the MBD1
original peptide sequence, only one tryptophan is present and it is present in the β-sheet
region instead of the loop region. The loop region is expected to bind with the DNA with
base stacking whereas the β-sheet region may only have weak electrostatic interactions
with the methylated DNA.
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The fluorescence binding study, indicated binding between the MBD1 peptide
and the methylated DNA. Tryptophan is the amino acid that possesses fluorescence
properties and can be monitored for changes in fluorescence based on DNA binding.
When bound to methylated DNA, the emission is quenched and therefore decreases its
fluorescence intensity. As the concentration of the DNA is increased, the fluorescence
emission decreases which indicates binding. This data can be graphed to produce a
binding curve. Higher concentrations of DNA were used in order to saturate binding
sites to determine an accurate dissociation constant. With the mutant peptides, a
decreased fluorescence intensity is expected and will indicate improved binding.
The thermal denaturation study provided the information need to determine the
melting temperature of the MDB1 peptide to be 49°C. This data will be compared to
future synthesized peptide sequences to determine the peptides stability and denaturation
characteristics. The peptide having the highest binding affinity for methylated DNA is
expected to have the most structure, highest melting temperature, and highest specificity,
but this must be confirmed by binding and structural studies. The CD study comparing
10µM samples of peptide, DNA, peptide and DNA (mixed), and peptide and DNA
(additive) indicate again that binding is present. Unlike the fluorescence binding study,
the peptide and DNA concentration are the same in the sample. The data shows the
structure of the peptide and DNA together. In order to be compared, the intensities of the
peptide and DNA structures were averaged and then plotted. The mixed and additive
graphs are not the same. They do not provide a signal for a specific structure but since
there is a difference between the additive and the mixed that is an indication of binding
rather than a simple average of the two signals. The structural difference will also be
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compared to future peptides in order to determine if the mutant bind more specifically
than the original MBD1 binding sequence. The future peptides will be analyzed with
binding and structural studies to determine a peptide sequence that can achieve high
affinity and sequence selectivity. These will be used to determine a structure-function
relationship for methylated DNA binding by peptides and proteins.
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